<DOC>
	<DOCNO>NCT00425425</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab may also make tumor cell sensitive radiation therapy . Drugs use chemotherapy , oxaliplatin fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving cetuximab , chemotherapy , radiation therapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase I/II trial study side effect best dose oxaliplatin fluorouracil give together cetuximab radiation therapy see well work treat patient stage II stage III esophageal cancer .</brief_summary>
	<brief_title>Cetuximab , Oxaliplatin , Fluorouracil , Radiation Therapy Treating Patients With Stage II Stage III Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose oxaliplatin fluorouracil administer cetuximab radiotherapy patient stage II III squamous cell carcinoma esophagus . ( Phase I ) - Determine response rate patient treat regimen . ( Phase II ) Secondary - Determine toxicity regimen patient . - Determine postoperative complication rate lethality patient treat regimen . - Determine R0 resection rate patient treat regimen . - Determine overall survival patient treat regimen . - Determine event-free survival patient treat regimen . - Determine metabolic response rate patient treat regimen . OUTLINE : This phase I , dose-escalation study oxaliplatin fluorouracil follow open-label , phase II study . - Phase I : Patients receive cetuximab IV 60-90 minute day -15 , -8 , 1 , 8 , 15 , 22 , 29 ; oxaliplatin IV 120 minute day 1 , 8 , 22 , 29 ; fluorouracil IV continuously day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 . Patients undergo radiotherapy day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 . Patients undergo radical esophagectomy 29-42 day completion chemoradiotherapy . Cohorts 3-6 patient receive escalate dos oxaliplatin fluorouracil maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive oxaliplatin fluorouracil phase I MTD determine phase I . Patients also receive cetuximab undergo radiotherapy radical esophagectomy phase I . After completion study therapy , patient follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 43 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma esophagus , meet follow criterion : Locally advanced disease ( T3T4 , N0N+ [ T2 , N0 cervical esophageal carcinoma ] ) Potentially resectable disease No distant metastasis ( M1b ) No tumor infiltration tracheobronchial system Bartels preoperative risk analysis &lt; 22 PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 Karnofsky PS 70100 % Creatinine ≤ 1.5 mg/dL OR creatinine clearance &gt; 60 mL/min Bilirubin ≤ 1.5 mg/dL ALT AST ≤ 2 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN WBC ≥ 3,000/mm³ Granulocyte count ≥ 2,000/mm³ Platelet count ≥ 100,000/mm³ No preexist polyneuropathy &gt; grade 1 No active uncontrolled infection PaO_2 ≥ 60 mm Hg room air FEV_1 ≥ 60 % normal No New York Heart Association class IIIV cardiac insufficiency Ejection fraction ≥ 35 % No angina pectoris ( rest stress ) unexplained interventional cardiology No myocardial infarction within past 6 month No histologically confirm liver cirrhosis No malignancy within past 5 year except carcinoma situ cervix nonmelanomatous skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior chemotherapy No prior radiotherapy thorax region No current esophageal stent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>stage IIA esophageal cancer</keyword>
	<keyword>stage IIB esophageal cancer</keyword>
	<keyword>stage IIIA esophageal cancer</keyword>
	<keyword>stage IIIB esophageal cancer</keyword>
	<keyword>stage IIIC esophageal cancer</keyword>
</DOC>